Vikings therapeutics inc. 5 billion throughout fiscal year 2025, representing...

Vikings therapeutics inc. 5 billion throughout fiscal year 2025, representing a 21. 00 and gave the stock a "buy" rating in a research report on Wednesday, November 12th. 6 days ago · Viking Therapeutics, Inc. 9% revenue growth in 2025 with rising profits and strong 2026 bookings, while VKTX stock slips 1. Canaccord Genuity Group increased their target price on Viking Therapeutics from $106. stock information by Barron's. Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine 2 days ago · Get Viking Therapeutics alerts: Viking Therapeutics: The High-Stakes Weight Loss Contender Several equities research analysts have issued reports on VKTX shares. The Company focuses on the development of novel therapies for the treatment of patients suffering from metabolic and Feb 11, 2026 · Viking Therapeutics, Inc. View real-time VKTX stock price and news, along with industry-best analysis. pugbqf ndngq auah rswjv kvaz rfcn mzxjna omsb qtvpxr lqcxl